In April, we anticipated a pullback for JNJ, and since then, the stock has dropped approximately 7%, aligning with our expectations. The current trend suggests further downward movement, reinforcing our previous analysis.
We are focusing on the support zone ranging from $134 to $116, with a potential lower bound at $109, the Corona-Low. The ongoing pullback could...
If you haven`t bought JNJ before the previous earnings:
Then analyzing the options chain and the chart patterns of JNJ Johnson & Johnson prior to the earnings report this week,
I would consider purchasing the 145usd strike price Puts with
an expiration date of 2025-1-17,
for a premium of approximately $7.55.
If these options prove to be profitable prior to the...
Johnson & Johnson (JNJ) quickly hit the $147.00 Target that we set on our very recent sell call (April 03, see chart below) and is now approaching the bottom of the massive 2-year Channel Down:
Even though based on the very reliable and consistent Sine Waves, the bottom might be a process that can take up to 2-months, the stock is low enough for medium-term...
Rallybio Corporation (Nasdaq: NASDAQ:RLYB ) is hitting the accelerator pedal after announcing a groundbreaking collaboration with Johnson & Johnson to combat fetal and neonatal alloimmune thrombocytopenia (FNAIT).
In a strategic move aimed at advancing therapeutic solutions for pregnant individuals at risk of FNAIT, Rallybio revealed plans for RLYB212, a...
Johnson & Johnson gives a very clear idea of its trend on the 1M timeframe. The price may be under the 1D MA50 but has reached the bottom of the multi year Channel Up that started at the bottom of the 2008-2009 crisis. Being neutral on the 1M technical outlook (RSI = 45.714, MACD = -1.180, ADX = 20.525) has historically been one of the best buy opportunities, in...
Johnson & Johnson (JNJ) got rejected on its 1D MA200 (orange trend-line) - 1D MA50 (blue trend-line) Resistance Zone. It has been practically trading sideways since the start of the year and based on the Sine Waves, that priced the new Top (Lower Highs trend-line) of the 2-year Channel Down pattern.
The expected completion of a Bearish Cross this week on the 1W...
The biggest pharma giants are easy to recognize. Johnson and Johnson, Pfizer, Moderna, Merck & Co, Danaher Corp, Thermo Fisher Scientific. All medications and pharmaceutical drugs come out of these drug corporations. Lab equipment, medical research, vaccines, and other life science developments come out of these conglomerate pharma giants.
Support and Resistance...
JNJ touched Support (1) at 153.20, a level holding since June 1st.
Along with Support (2) at 150.10 are the major buy levels for the long term.
The medium term Resistance is the MA200 (1d).
Trading Plan:
1. Buy on the current market price.
2. If Support (1) breaks, buy on Support (2).
Targets:
1. 162.00 (expected contact point with the MA200 (1d)).
2. 161.00...
It is plausible to consider that Johnson & Johnson's decision to spin off Kenvue might be linked to an effort to mitigate potential legal liabilities stemming from its talc-based products, which have been implicated in cases of cancer in the US and Canada. This strategic maneuver could potentially offer a layer of legal protection. Shareholders are expected to...
Analyzing the options chain of JNJ Johnson & Johnson prior to the earnings report this week,
I would consider purchasing the 160usd strike price Calls with
an expiration date of 2023-9-15,
for a premium of approximately $3.85.
If these options prove to be profitable prior to the earnings release, I would sell at least half of them.
Looking forward to read your...
Johnson & Johnson is trading inside an Ascending Triangle pattern with the 1D technicals neutral (RSI = 49.652, MACD = -0.360, ADX = 36.021). The 1D MACD is close to making a Buy Cross so today's cross over the 1D MA50 is a first buy signal, that targets the 1D MA200 (TP = 165.00).
If the price crosses over the R1 (167.25) we will buy again targeting the R2 (TP...
Analyzing the options chain of JNJ Johnson & Johnson prior to the earnings report this week, I would consider purchasing
at the money Calls with a 165usd strike price and an expiration date of 2023-4-21, for a premium of approximately $2.36.
If these options prove to be profitable prior to the earnings release, I would sell at least half of them.
I am interested...
Hi,
The market has made some pretty good moves up and the current slight correction is bringing prices back to technically good levels and Johnson & Johnson is one of them.
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer goods.
Technically, it has been quite difficult...
Johnson & Johnson has rejected the Heartline of the Equidistant Channel while showing Bearish Divergence on the MACD and RSI and as a result i now think it will be heading for a minimum .382-.618 Retrace and i will be playing it via monthly put options.
Johnson & Johnson (JNJ) has been trading within a long-term Bullish Megaphone pattern since the January 26 2021 High. The pattern has been having very structured Higher Highs and Higher Lows.
At the moment the stock is on a bullish leg, after rebounding exactly on the 1D MA50 (blue trend-line) on November 11 and is also above the 1D MA200 (orange trend-line). The...
JNJ feeling weak right now while moving within two descending channels. Currently the price is at the top of the minor channel, which should increase the selling pressure very soon.
NYSE:JNJ
The Conservative Stop offers less exposition and a great Risk/Reward Ratio of 5 at the risk of being too tight .While the wide stop offers much more room for the trade at the expense of a lesser Risk/Reward Ratio around 3.5 .
Whatever your style ,trading is a game of probabilities and the bulk of the profit if not all the significant profit is realised...
